Definium Therapeutics, Inc.
NASDAQ:DFTXBiotechnology
-$0.41 today
- Market cap
- $3.99B
- Beta
- 2.38
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.18
Volume 1.91M
Average 2.67M
DFTX Operating Expenses
Total costs of running the business that are not directly tied to producing goods or services sold.
Definium Therapeutics, Inc.NASDAQ: DFTX
Operating Expenses · Q3 FY2026 · quarter ended Sep 2026
Operating expenses grows, but more slowly than its trailing trend
Q3 FY2026 operating expenses of $72.28M rose 58.3% year over year, behind the +68.1% change in trailing-twelve-month operating expenses. Sequentially, it fell 3.7% from the prior quarter. Over 3 fiscal years it compounded at +35.9% a year.
Context
- Operating expenses increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +58.3% toward the trailing-twelve-month pace of +68.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Operating Expenses history
USD · from the income statement
- Latest · FY2025
- 166.31M USD
- Year-over-year change
- +60.9%
- 4-year CAGR
- +15.4%
| Period | Period end | Operating Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 166.31M | +60.9% |
| FY2024 | 2024-12-31 | 103.39M | +14.0% |
| FY2023 | 2023-12-31 | 90.7M | +36.7% |
| FY2022 | 2022-12-31 | 66.33M | -29.3% |
| FY2021 | 2021-12-31 | 93.85M | — |
Operating Expenses vs competitors
How DFTX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating expenses is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +68.1% is the 4th highest of 10, against a peer median of +33.9%.
- Over three fiscal years its annual growth of +35.9% compares with a peer median of +40.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $912.58M USD | +33.9% | +50.1% | 117.5% | |
| LTM Sep 2026 | $329.22M USD | +502.1% | +75.3% | — | |
DFTXDefinium Therapeutics, Inc. | LTM Sep 2026 | $254.15M USD | +68.1% | +35.9% | — |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | $218.08M USD | -20.5% | +20.2% | — |
| LTM Mar 2026 | $209.6M USD | +141.3% | +76.5% | — | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $141.71M USD | +52.6% | +129.5% | 708.6% |
| LTM Mar 2026 | $66.42M USD | +28.9% | +25.5% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $46.78M USD | — | +121.2% | — |
| LTM Jun 2026 | $35.14M USD | +117.4% | -15.7% | — | |
| FY2025 | A$19.89M AUD | -15.0% | -0.6% | 365.6% | |
| LTM Mar 2026 | -$55.19M USD | -179.1% | +31.6% | — | |
| Peer median (excluding DFTX) | — | +33.9% | +40.9% | 365.6% | |
Competitors are the stored peer set for DFTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 3.16M | 527K | 0 |
| Gross Profit | 0 | 0 | (3.16M) | (527K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 34.79M | 36.17M | 48.96M | 65.3M | 117.67M |
| Selling, General & Admin | 59.07M | 30.16M | 41.74M | 38.62M | 48.64M |
| Operating Expenses | 93.85M | 66.33M | 90.7M | 103.39M | 166.31M |
| Depreciation & Amortization | 2.62M | 3.18M | 3.16M | 527K | 0 |
| EBITDA | (91.22M) | (52.12M) | (92.57M) | (105.87M) | (178.31M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (93.85M) | (66.33M) | (93.87M) | (103.92M) | (166.31M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 1.5M | 5.58M | 11.56M | 10.96M |
| Interest Expense | 359K | 1.5M | 920K | 2.28M | 5.48M |
| Other Income / Expenses | (339K) | 9.54M | (1.87M) | (4.76M) | (17.48M) |
| Income Before Tax | (94.19M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (1.16M) | 0 | 0 | 0 | 0 |
| Net Income | (93.04M) | (56.8M) | (95.73M) | (108.68M) | (183.79M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (3.40) | (1.53) | (2.44) | (1.54) | (2.06) |
| EPS (Diluted) | (3.40) | (1.53) | (2.44) | (0.15) | (2.06) |
| Weighted Avg Shares | 27.38M | 30.86M | 39.16M | 70.46M | 89.33M |
| Weighted Avg Shares (Diluted) | 27.38M | 30.86M | 39.16M | 704.61M | 89.33M |
Definium Therapeutics, Inc.
NASDAQ:DFTX
Intrinsic Alpha fair value
Locked
Current Price
$29.12
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.